Literature DB >> 33668689

Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro.

Patrícia F Lainetti1, Antonio F Leis-Filho2, Priscila E Kobayashi2, Laíza S de Camargo1, Renee Laufer-Amorim2, Carlos E Fonseca-Alves1,3, Fabiana F Souza1.   

Abstract

Rapamycin is an antifungal drug with antitumor activity and acts inhibiting the mTOR complex. Due to drug antitumor potential, the aim of this study was to evaluate its effect on a preclinical model of primary mammary gland tumors and their metastases from female dogs. Four cell lines from our cell bank, two from primary canine mammary tumors (UNESP-CM1, UNESP-CM60) and two metastases (UNESP-MM1, and UNESP-MM4) were cultured in vitro and investigated for rapamycin IC50. Then, cell lines were treated with rapamycin IC50 dose and mRNA and protein were extracted in treated and non-treated cells to perform AKT, mTOR, PTEN and 4EBP1 gene expression and global proteomics by mass spectrometry. MTT assay demonstrated rapamycin IC50 dose for all different tumor cells between 2 and 10 μM. RT-qPCR from cultured cells, control versus treated group and primary tumor cells versus metastatic tumor cells, did not shown statistical differences. In proteomics were found 273 proteins in all groups, and after data normalization 49 and 92 proteins were used for statistical analysis for comparisons between control versus rapamycin treatment groups, and metastasis versus primary tumor versus metastasis rapamycin versus primary tumor rapamycin, respectively. Considering the two statistical analysis, four proteins, phosphoglycerate mutase, malate dehydrogenase, l-lactate dehydrogenase and nucleolin were found in decreased abundance in the rapamycin group and they are related with cellular metabolic processes and enhanced tumor malignant behavior. Two proteins, dihydrolipoamide dehydrogenase and superoxide dismutase, also related with metabolic processes, were found in higher abundance in rapamycin group and are associated with apoptosis. The results suggested that rapamycin was able to inhibit cell growth of mammary gland tumor and metastatic tumors cells in vitro, however, concentrations needed to reach the IC50 were higher when compared to other studies.

Entities:  

Keywords:  cell culture; female dog; neoplasia; protein

Mesh:

Substances:

Year:  2021        PMID: 33668689      PMCID: PMC7956669          DOI: 10.3390/molecules26051213

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  79 in total

Review 1.  Targeting lactate metabolism for cancer therapeutics.

Authors:  Joanne R Doherty; John L Cleveland
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  Structure, Function, Involvement in Diseases and Targeting of 14-3-3 Proteins: An Update.

Authors:  Ylenia Cau; Daniela Valensin; Mattia Mori; Sara Draghi; Maurizio Botta
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

3.  Proteome of metastatic canine mammary carcinomas: similarities to and differences from human breast cancer.

Authors:  Robert Klopfleisch; Patricia Klose; Christoph Weise; Angelika Bondzio; Gerd Multhaup; Ralf Einspanier; Achim D Gruber
Journal:  J Proteome Res       Date:  2010-11-02       Impact factor: 4.466

Review 4.  Nucleolin-based targeting strategies for cancer therapy: from targeted drug delivery to cytotoxic ligands.

Authors:  Sofia Romano; Nuno Fonseca; Sérgio Simões; João Gonçalves; João Nuno Moreira
Journal:  Drug Discov Today       Date:  2019-07-02       Impact factor: 7.851

5.  Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.

Authors:  Melissa C Paoloni; Christina Mazcko; Elizabeth Fox; Timothy Fan; Susan Lana; William Kisseberth; David M Vail; Kaylee Nuckolls; Tanasa Osborne; Samuel Yalkowsy; Daniel Gustafson; Yunkai Yu; Liang Cao; Chand Khanna
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

6.  Determinants of rapamycin sensitivity in breast cancer cells.

Authors:  Woo-Chul Noh; Wallace H Mondesire; Junying Peng; Weiguo Jian; Haixia Zhang; JinJiang Dong; Gordon B Mills; Mien-Chie Hung; Funda Meric-Bernstam
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

7.  Targeting the Achilles' heel of cancer cells via integrin-mediated delivery of ROS-generating dihydrolipoamide dehydrogenase.

Authors:  Avraham Dayan; Gideon Fleminger; Osnat Ashur-Fabian
Journal:  Oncogene       Date:  2019-03-14       Impact factor: 9.867

8.  Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion.

Authors:  Yao-An Wen; Bo-Wei Zhou; Dao-Jun Lv; Fang-Peng Shu; Xian-Lu Song; Bin Huang; Chong Wang; Shan-Chao Zhao
Journal:  Asian J Androl       Date:  2018 Mar-Apr       Impact factor: 3.285

9.  Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect.

Authors:  Aoxing Cheng; Peng Zhang; Bo Wang; Dongdong Yang; Xiaotao Duan; Yongliang Jiang; Tian Xu; Ya Jiang; Jiahui Shi; Chengtao Ding; Gao Wu; Zhihong Sang; Qiang Wu; Hua Wang; Mian Wu; Zhiyong Zhang; Xin Pan; Yue-Yin Pan; Ping Gao; Huafeng Zhang; Cong-Zhao Zhou; Jing Guo; Zhenye Yang
Journal:  Nat Commun       Date:  2019-12-05       Impact factor: 14.919

10.  Correction: Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity.

Authors:  D Zhang; N Jin; W Sun; X Li; B Liu; Z Xie; J Qu; J Xu; X Yang; Y Su; S Tang; H Han; D Chen; J Ding; M Tan; M Huang; M Geng
Journal:  Oncogene       Date:  2020-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.